1
|
Wang
|
2018
|
China
|
English
|
Osteoarthritis
|
147
|
74
|
73
| |
65 ± 13.1
|
63.6 ± 11.5
| |
E
|
C
| |
2 g of TXA (4 tablets of 500 mg) by oral bolus appropriately 2 h before incision as a preoperative dose, a postoperative dose of 1 g was repeated 6 and 12 h after surgery, respectively
|
Received an intraarticular administration of 100 mL of saline solution containing a 3 g dose of TXA
| |
No
|
Duration of surgery, the total blood loss, transfusion risk, Hb, ROM, DVT, PE
|
2
|
Huang
|
2017
|
China
|
English
|
Osteoarthritis
|
150
|
50
|
50
|
50
|
66.2 ± 8.3
|
65.1 ± 6.8
|
65.8 ± 6.3
|
I
|
D
|
F
|
Treated with a tourniquet multiple doses of intravenous TXA (20 mg/kg 5 to 10 min before the skin incision and 10 mg/kg 3, 6, 12, and 24 h later) along with 1 g of topical TXA
|
Multiple doses of intravenous TXA (20 mg/kg5 to 10 min before the skin incision and 10 mg/kg 3, 6, 12, and 24 h later) along with 1 g of topical TXA
|
Treated with the tourniquet only
|
Yes
|
ROM, Flexion contracture, Hb, the total blood loss, duration of surgery, transfusion risk, DVT, PE
|
3
|
Tzatzairis
|
2016
|
Greece
|
English
|
OSTEOARTHRITIS
|
120
|
40
|
40
|
40
|
68.58 ± 7.50
|
69.55 ± 6.61
|
69.10 ± 8.68
|
A
|
B
|
C
|
Did not receive TXA.
|
1 g (100 mg/mL) of TXA, in 100 mL normal saline, intravenously 10 min before incision
|
1 g (100 mg/mL) of TXA, in 100 mL normal saline was administered intra-articularly after joint capsule closure.
|
Yes
|
Blood loss, transfusion risk, Hb, duration of surgery
|
4
|
Nielsen
|
2016
|
Denmark
|
English
|
Osteoarthritis
|
60
|
30
|
30
| |
65.5 ± 7.8
|
63.2 ± 8.6
| |
B
|
D
| |
Received 1 g of TXA administered intravenously only and 100 mL of saline solution administered intra-articularly
|
1 g of TXA administered intravenously during the induction of anesthesia and 3 g diluted in 100 mL of saline solution (0.9%) administered intra-articularly after closure of the capsule
| |
No
|
Duration of surgery, the total blood loss, transfusion risk, Hb1d
|
5
|
Jain
|
2016
|
India
|
English
|
Osteoarthritis
|
119
|
60
|
59
| |
70.0 ± 6.56
|
68.27 ± 8.66
| |
B
|
D
| |
Given IVTXA as a preoperative and postoperative dose given 3 and 6 h after surgery
|
topical TXA solution was applied intra-articularly about 5 min before closure of arthrotomyin addition IV doses
| |
No
|
Duration of surgery, transfusion risk, the total blood loss, DVT, Hb
|
6
|
May
|
2016
|
USA
|
English
|
Osteoarthritis
|
131
|
69
|
62
| |
65.0 ± 9.6
|
63.0 ± 10.6
| |
G
|
H
| |
1 g of TXA in 100 mL of normal saline (after anesthetic induction and before tourniquet inflation) and 1 dose of 50 mL of normal saline without TXA (administered after capsular closure)
|
2 g of TXA was prepared for the topical dose in 50 mL of saline, and 100 mL of normal saline without TXA
| |
No
|
Duration of surgery, 0/1d Hb,3d total blood loss, PE, DVT
|
7
|
Drosos
|
2016
|
Greece
|
English
|
Osteoarthritis
|
90
|
30
|
30
|
30
|
71.77 ± 6.5
|
69.27 ± 7.21
|
71.1 ± 6.32
|
F
|
G
|
H
|
No TXA
|
Received 1 g TXA intravenously
|
1 g TXA in 30 ml normal saline (a solution of 40 ml) was applied topically
|
yes
|
Hb4d, the total blood loss, transfusion risk
|
8
|
Yang
|
2015
|
China
|
English
|
Osteoarthritis, traumatic arthritis or rheumatoid arthritis
|
80
|
40
|
40
| |
69 ± 5
|
67 ± 6
| |
F
|
H
| |
20 mL of normal saline solution
|
Receive 500 mg of TXA in 20 mL of normal saline solution
| |
No
|
Duration of surgery, Transfusion risk, Hb, DVT, PE
|
9
|
Keyhani
|
2015
|
Iran
|
English
|
Osteoarthritis
|
120
|
40
|
40
|
40
|
68.4 ± 10.4
|
67 ± 11.9
|
63.9 ± 9
|
G
|
H
|
F
|
Received 500 mg of TXA in 100 cc saline at the end of the surgery
|
Received an intra-articular dose of 3 g of TXA in 100 mL normal saline. Half of the solution was used to irrigate the joint before joint closure.
|
Did not receive TXA
|
Yes
|
Hb4d, the total blood loss, transfusion risk, DVT, PE
|
10
|
Patel
|
2014
|
USA
|
English
|
Osteoarthritis
|
89
|
42
|
47
| |
64.9 ± 7.8
|
64.8 ± 9.7
| |
G
|
H
| |
Versus IV administration of 10 mg/kg, 10 min prior to tourniquet deflation.
|
Administered2.0gTXAin100mlofnormal saline directly into the surgical site and bathed in the solution, undisturbed for 2 min prior to tourniquet release
| |
Yes
|
Hb, transfusion risk, DVT
|
11
|
Good
|
2003
|
Sweden
|
English
|
Osteoarthritis
|
51
|
24
|
27
| |
72(50–84)
|
72(46–83)
| |
F
|
G
| |
Placebo 10 mg/kg i.v. just before tourniquet release and 3 h later
|
TXA 10 mg/kg i.v. just before tourniquet release and 3 h later
| |
Yes
|
Blood loss, DVT, transfusion risk
|
12
|
Tanaka
|
2001
|
Japan
|
English
|
Osteoarthritis, rheumatoid arthritis
|
53
|
26
|
27
| |
65(58–70)
|
65(59–69)
| |
F
|
G
| |
Saline twice, 10 min before surgery and on deflation of the tourniquet
|
10 mg/kg of TNA 10 min before surgery and again 10 min before deflation of the tourniquet
|
Saline 10 min before surgery and 20 mg/kg of TNA 10 min before deflation of the tourniquet
|
Yes
|
Hb1/2/4/7d, duration of surgery, transfusion risk, the total blood loss
|
13
|
Jansen
|
1999
|
Belgium
|
English
|
Osteoarthritis, rheumatoid arthritis
|
42
|
21
|
21
| |
71.0(64–84)
|
70.7(62–80)
| |
F
|
G
| |
Normal saline of 15mgkg-1 was administered 30 min before surgery + every 8 h 3 days after surgery
|
TXA (15mgkg-1) was administered 30 min before surgery + every 8 h 3 days after surgery
| |
Yes
|
Duration of surgery, the total blood loss, transfusion risk, DVT
|
14
|
BENON
|
1996
|
Sweden
|
English
|
Osteoarthritis, aseptic bone necrosis
|
86
|
43
|
43
| |
76 ± 7
|
74 ± 7
| |
G
|
F
| |
IV 10 mg/kg TXA
|
A median time of 12 min (1 to 40) before deflation of the tourniquet, repeated after 3 h, 10 mg/kg placebo
| |
Yes
|
Duration of surgery, the total blood loss, DVT, PE, ROM
|